Abortion Bans Linked to Shifts in Spontaneous Abortion Management

Navigating Spontaneous Abortion Care in a Changing Landscape

Spontaneous abortion, affecting approximately a quarter of all clinically identified pregnancies, represents the most common complication of early gestation [1, 2]. Effective management is crucial, with options typically including expectant, medication, or surgical approaches, each carrying distinct considerations for patient experience and outcomes [1, 3]. The combination of mifepristone and misoprostol is recognized as an evidence-based medication regimen for managing early pregnancy loss, often demonstrating superior efficacy compared to misoprostol alone in various contexts, including missed miscarriage and induction after fetal demise [4, 5]. However, the landscape of reproductive healthcare is subject to evolving legal and policy frameworks that can influence clinical practice. A new study now offers fresh insights into how these external factors may be reshaping the delivery of care for spontaneous abortion [6].

Examining Policy's Influence on Clinical Practice

The study aimed to assess the association of state-level abortion bans with spontaneous abortion management and receipt of the evidence-based medication regimen mifepristone plus misoprostol among commercially insured individuals in the United States. This objective is particularly relevant given that spontaneous abortion is the most common complication of early pregnancy, affecting a significant portion of patients in early gestation. Furthermore, the management of spontaneous abortion requires the same treatment options as induced abortion, meaning policy changes impacting one can directly influence the other.

Despite the clinical overlap and the high incidence of spontaneous abortion, there are limited data available on the influence of abortion bans on spontaneous abortion management in the United States. This knowledge gap underscores the importance of the current research, which sought to provide clarity on how evolving legal frameworks might be shaping clinical practice for this common obstetric complication.

Study Design and Cohort Characteristics

The researchers conducted a retrospective cross-sectional study to investigate the impact of state-level abortion bans on spontaneous abortion management. This analysis utilized the Merative MarketScan Commercial Claims database, a comprehensive source of healthcare claims for commercially insured individuals in the United States. The study cohort comprised 123,598 individuals aged 15 to 45 years who experienced a spontaneous abortion at fewer than 77 days’ gestation. Data were collected over an extended period, from January 1, 2018, through September 30, 2024, allowing for a robust examination of trends before and after policy changes. To assess the influence of these policy shifts, a difference-in-differences framework was employed, comparing management changes from a prepolicy period, spanning January 2018 to May 2022, to a postpolicy period, from July 2022 to September 2024.

The study specifically compared outcomes in 14 states with trigger bans against those in 17 comparison states. The exposures under investigation were state-level abortion bans that restricted abortion to fewer than 6 weeks’ gestation, which were triggered by the Dobbs v Jackson Women’s Health Organization decision on June 24, 2022. The main outcomes and measures included the type of spontaneous abortion management, categorized as expectant, medication, or surgical. Furthermore, among individuals who received medication management, the researchers assessed the receipt of mifepristone plus misoprostol versus misoprostol alone. The overall study population of 123,598 individuals had a mean age of 30.17 years (standard deviation, 6.25 years). Of these, 54,181 individuals were located in trigger ban states, while 69,417 individuals resided in comparison states.

Shifts in Management Approaches

The analysis revealed distinct shifts in spontaneous abortion management following the implementation of state-level abortion bans. In adjusted models, trigger bans were associated with a 2.8 percentage point increase in expectant management (95% CI, 1.0-4.6). This change was evident in the detailed data: in trigger ban states, expectant management increased from 26,260 of 35,855 individuals (73.2%) during the prepolicy period to 14,048 of 18,326 individuals (76.7%) in the postpolicy period. In contrast, comparison states saw a more modest shift in expectant management, moving from 32,927 of 47,232 individuals (69.7%) prepolicy to 15,617 of 22,185 individuals (70.4%) postpolicy.

Conversely, the study identified a decrease in medication-based approaches. Trigger bans were associated with a 2.2 percentage point decrease in medication management (95% CI, -3.5 to -0.9). Specifically, in trigger ban states, medication management declined from 3,183 of 35,855 individuals (8.9%) prepolicy to 1,446 of 18,326 individuals (7.9%) postpolicy. In comparison states, medication management actually saw an increase, from 5,054 of 47,232 individuals (10.7%) prepolicy to 2,687 of 22,185 individuals (12.1%) postpolicy. The researchers also noted that trigger bans showed no significant change in surgical management for spontaneous abortion.

Impact on Medication Regimen Choice

Beyond the overall shift in management approaches, the study also detailed changes in specific medication regimens for spontaneous abortion. Among individuals who received medication, the researchers found that state-level trigger bans were associated with a relative 13.8 percentage point increase in misoprostol-only regimens (95% CI, 9.0-18.6). This finding indicates a move away from the evidence-based combination of mifepristone plus misoprostol toward a less effective single-agent approach in states with abortion restrictions. The detailed data showed that in trigger ban states, the proportion of misoprostol-only regimens remained high, shifting from 3,124 of 3,183 individuals (98.1%) during the prepolicy period to 1,401 of 1,446 individuals (96.9%) in the postpolicy period.

In contrast, comparison states, which did not implement trigger bans, demonstrated a different trend in medication use. In these states, the proportion of misoprostol-only regimens decreased from 4,250 of 5,054 individuals (84.1%) prepolicy to 1,840 of 2,687 individuals (68.5%) postpolicy. This suggests that in the absence of restrictive policies, clinicians in comparison states were increasingly able to utilize the more effective combined regimen of mifepristone and misoprostol. The persistent reliance on misoprostol-only regimens in trigger ban states, despite its lower efficacy compared to the combined regimen, highlights a potential decrease in optimal management options for patients experiencing spontaneous abortion in these regions.

Clinical Implications for Spontaneous Abortion Care

The study's findings carry significant implications for the clinical management of spontaneous abortion, particularly in states with restrictive abortion policies. Overall, the researchers observed that state-level abortion bans were associated with a shift in spontaneous abortion management away from medication and toward expectant approaches. This shift, detailed in earlier sections, indicates a move away from active intervention via medication, which can offer a more predictable and often quicker resolution, toward a more passive, watchful waiting approach. For practicing physicians, this suggests a potential limitation in the therapeutic toolkit available for patients experiencing early pregnancy loss, potentially leading to prolonged uncertainty and increased burden for individuals.

Further compounding these clinical challenges, the study also revealed that state-level abortion bans were associated with persistent reliance on suboptimal misoprostol-only regimens in ban states. As previously noted, the evidence-based standard for medication management of spontaneous abortion often involves the combined use of mifepristone and misoprostol, which offers superior efficacy compared to misoprostol alone. The continued high proportion of misoprostol-only regimens in ban states, even as comparison states saw a decrease in this practice, underscores a divergence from optimal care. Collectively, these findings suggest a decrease in management options for individuals with spontaneous abortion in ban states, potentially impacting the effectiveness, safety, and patient experience of care for this common and often distressing complication of early pregnancy.

References

1. Ho AL, Hernández A, Robb JM, et al. Spontaneous Miscarriage Management Experience: A Systematic Review. Cureus. 2022. doi:10.7759/cureus.24269

2. Hooker AB, Lemmers M, Thurkow AL, et al. Systematic review and meta-analysis of intrauterine adhesions after miscarriage: prevalence, risk factors and long-term reproductive outcome. Human Reproduction Update. 2013. doi:10.1093/humupd/dmt045

3. Huchon C, Drioueche H, Koskas M, et al. Operative Hysteroscopy vs Vacuum Aspiration for Incomplete Spontaneous Abortion: A Randomized Clinical Trial.. 2023. doi:10.1001/jama.2023.3415

4. Shami M, Larki M, Makvandi S, Azari M. Inducing labor after fetal demise: a systematic review and meta-analysis of the efficacy and safety of mifepristone and misoprostol combination versus misoprostol alone. BMC Pregnancy and Childbirth. 2025. doi:10.1186/s12884-025-07528-w

5. Chu J, Devall A, Beeson L, et al. Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial. The Lancet. 2020. doi:10.1016/s0140-6736(20)31788-8

6. Rodriguez MI, Fuerst M, Schrote K. Management of Spontaneous Abortion Among Commercially Insured Individuals in the United States After Dobbs v Jackson.. JAMA. 2026. doi:10.1001/jama.2026.6344